ELECTROTHERAPY SYSTEM MARKET ANALYSIS

Electrotherapy System Market, By Technology [Transcutaneous Electrical Nerve Stimulation (TENS), Neuromuscular Electrical Stimulation (NMES), Inferential Current (IFC), Percutaneous Electrical Nerve Stimulation (PENS), Electronic Muscle Stimulator (EMS), Spinal Cord Stimulation (SCS), Electro-acupuncture (EA) and Others], By Application (Chronic Wound Healing, Neuromuscular Dysfunction, Pain Management, Tissue Repair, Musculoskeletal Disorder, Physical Therapy, Iontophoresis, Others), By Therapy (Extracorporeal Shock Wave Therapy, Magnetic Field Therapy, Ultrasound Therapy, Microcurrent Therapy, Interferential Current Therapy and Others), By End User (Hospitals, Rehabilitation Centers, Clinics) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : May 2023
Code : CMI3034
Pages :221
Formats :
Excel and PDF
Industry : Medical Devices

Market News

Global Electrotherapy System Market : Key Developments

In March 2022, Cionic, a medical device company, announced that the Neural Sleeve received the U.S. Food and Drug Administration approval. The Neural Sleeve is the first algorithm-powered bionic garment designed to help those with mobility issues due to multiple sclerosis, stroke, cerebral palsy, and other conditions, regain functional movement.

In January 2022, TensCare Ltd, a medical device company, showcased its new-to-market products, which offer the latest in transcutaneous electrical nerve stimulation (TENS) indicated to be used for drug-free pain relief in the long-term treatment of chronic pain conditions such as back ache, diabetic neuropathy, sciatica, osteo-arthritis and the relief of the acute pain of childbirth. The TensCare Ltd showcased its transcutaneous electrical nerve stimulation (TENS) at the ABHI UK Pavilion at Arab Health 2022 conference.

In March 2021, Zynex Medical, a medical technology and biotechnology company, announced to attend the Raymond James Life Sciences and MedTech Conference 2022, to showcase all its pain management device and market its products in the different countries of Latin America.

In technology segment, Spinal Cord Stimulation (SCS) is expected to be a dominant segment in North America due to the increasing product approval in North America. For instance, in May 2022, Abbott Laboratories, a pharmaceutical and medical technology company, announced the approval of the U.S. FDA for its new Proclaim Plus spinal cord stimulation system, which provides tailored relief to multiple pain.

In application segment, pain management segment is dominant in hospitals due to increasing hospital admissions and visits for the sports injury, traumatic pains and accidental injury. For instance, in December 2022, according to the data published by the National Center for Biotechnology Information, it was estimated that in North America about 52,300 people visit hospital for pain management due to traumatic incidence in the year 2022.